, Volume 116, Issue 1, pp 56–64 | Cite as

Behavioural and pharmacological characterisation of the elevated “zero-maze” as an animal model of anxiety

  • Jon K. Shepherd
  • Savraj S. Grewal
  • Allan Fletcher
  • David J. Bill
  • Colin T. Dourish
Original Investigations


The elevated “zero-maze” is a modification of the elevated plus-maze model of anxiety in rats which incorporates both traditional and novel ethological measures in the analysis of drug effects. The novel design comprises an elevated annular platform with two opposite enclosed quadrants and two open, removing any ambiguity in interpretation of time spent on the central square of the traditional design and allowing uninterrupted exploration. Using this model, the reference benzodiazepine anxiolytics, diazepam (0.125–0.5 mg/kg) and chlordiazepoxide (0.5–2.0 mg/kg) significantly increased the percentage of time spent in the open quadrants (% TO) and the frequency of head dips over the edge of the platform (HDIPS), and reduced the frequency of stretched attend postures (SAP) from the closed to open quadrants. In contrast, the anxiogenic drugm-chlorophenyl-piperazine (mCPP; 0.25–1.0 mg/kg) induced the opposite effects, decreasing %TO and HDIPS, and increasing SAP. The 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT; 0.001–0.1 mg/kg) had no effects on either %TO or HDIPS, but did decrease SAP at 0.01 mg/kg although not at higher or lower doses. Similarly, the 5-HT3 receptor antagonist, ondansetron (0.0001–1.0 mg/kg) decreased SAP and increased %TO at 0.01 mg/kg, but not at other doses. The present data suggest that a combination of the novel “zero-maze” design and a detailed ethological analysis provides a sensitive model for the detection of anxiolytic/anxiogenic drug action.

Key words

Anxiety Elevated zero-maze Rat Diazepam Chlordiazepoxide mCPP 8-OH-DPAT Ondansetron Head dips Stretched attend postures 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Baldwin HA, File SE (1988) Reversal of increased anxiety during benzodiazepine withdrawal: evidence for an anxiogenic endogenous ligand for the benzodiazepine receptor. Brain Res Bull. 20: 603–606Google Scholar
  2. Barnett SA (1966) The rat: a study in behavior. Aldine, ChicagoGoogle Scholar
  3. Barrett JE, Glesson S (1991) Anxiolytic effects of 5-HT1A agonists, 5-HT3 antagonists and benzodiazepines: conflict and drug discrimination studies. In: Rodgers RJ, Cooper SJ (eds) 5-HT1A agonists, 5-HT3 antagonists and benzodiazepines — their comparative behavioural pharmacology. Wiley, Chichester, pp 59–105Google Scholar
  4. Benjamin D, Lal H, Meyerson LR (1990) The effects of 5-HT1B characterizing agents in the mouse elevated plus-maze. Life Sci 47: 195–203Google Scholar
  5. Blanchard DC, Blanchard RJ, Tom P, Rodgers RJ (1990) Diazepam changes risk assessment in an anxiety/defense test battery. Psychopharmacology 101: 511–518Google Scholar
  6. Blanchard DC, Weatherspoon A, Shepherd JK, Rodgers RJ (1991) “Paradoxical” effects of morphine on antipredator defense reactions in wild and laboratory (R. norvegicus) rats. Pharmacol Biochem Behav 40: 819–828Google Scholar
  7. Butler A, Hill JM, Ireland SJ, Jordan CC, Tyers MB (1988) Pharmacological properties of GR 38032F, a novel antagonist at 5-HT3 receptors. Br J Pharmacol 94: 397–412Google Scholar
  8. Cole JC, Rodgers RJ (1994) An ethological analysis of the effects of chlordiazepoxide and bretazenil (Ro 16-6028) in the murine elevated plus-maze. Behav Pharmacol (in press)Google Scholar
  9. Costall B, Naylor, RJ (1991) Anxiolytic effects of 5-HT3 antagonists in animals. In: Rodgers RJ, SJ Cooper SJ (eds) 5-HT1A agonists, 5-HT3 antagonists and benzodiazepines — their comparative behavioural pharmacology. Wiley, Chichester, pp 133–157Google Scholar
  10. Costall B, Kelly ME, Tomkins DM, Tyers MB (1989) Profile of action of diazepam and 5-HT3 receptor antagonists in the elevated X-maze. J Psychopharmacol 3: 10PGoogle Scholar
  11. Cox CP (1987) A handbook of introductory statistical methods. Wiley, New YorkGoogle Scholar
  12. Critchley MAE, Handley SL (1987) Effects in the X-maze anxiety model of agents acting at 5-HT1 and 5-HT2 receptors. Psychopharmacology 93: 502–506Google Scholar
  13. Critchley MAE, Njung'e K, Handley SL (1992) Actions and some interactions of 5-HT1A ligands in the elevated X-maze and effects of dorsal raphe lesions. Psychopharmacology 106: 484–490Google Scholar
  14. Dourish CT (1987) Brain 5-HT1A receptors and anxiety. In: Dourish CT, Ahlenius S, Hutson PH (eds) Brain 5-HT1A receptors. Ellis Horwood, Chichester, pp 261–277Google Scholar
  15. Dunn RW, Corbett R, Fielding S (1989) Effects of 5-HT1A receptor agonists and NMDA receptor antagonists in the social interaction test and the elevated plus-maze. Eur J Pharmacol 169: 1–10Google Scholar
  16. Falter U, Gower AJ, Gobert J (1992) Resistance of baseline activity in the elevated plus-maze to exogenous influences. Behav Pharmacol 3: 123–128Google Scholar
  17. File SE (1991) The biological basis of anxiety. In: Meltzer HY, Nerozzi D (eds) Current practices and future developments in the pharmacotherapy of mental disorders. Excerpta Medica, Amsterdam, pp 159–166Google Scholar
  18. File SE, Johnston AJ (1989) Lack of effects of 5-HT3 receptor antagonists in the social interaction and elevated plus-maze tests of anxiety in the rat. Psychopharmacology 99: 248–251Google Scholar
  19. Grant EC, Mackintosh JH (1963) A comparison of the social postures of some common laboratory rodents. Behaviour 21: 246–259Google Scholar
  20. Griebel G, Misslin R, Pawlowski M, Vogel E (1991)m-Chlorophenylpiperazine enhances neophobic and anxious behaviour in mice. Neuroreport 2: 627–629Google Scholar
  21. Grossen NE, Kelley MJ (1973) Species-specific behavior and acquisition of avoidance behavior in rats. J Comp Physiol Psychol 81: 307–310Google Scholar
  22. Handley SL (1991) Serotonin in animal models of anxiety: the importance of stimulus and response. In: Cowen P, Idzikowski C (eds) Serotonin, sleep and mental disorder. Wrightson Biomedical Publications, Petersfield, pp 89–115Google Scholar
  23. Handley SL, Mithani S (1984) Effects of alpha-adrenoceptor agonists and antagonists in a maze-exploration model of “fear”-motivated behaviour. Naunyn Schmiedeberg's. Arch Pharmacol 327: 1–5Google Scholar
  24. Handley SL, McBlane JW (1993) 5HT drugs in animal models of anxiety. Psychopharmacology 112: 13–20Google Scholar
  25. Hoyer D (1988) Functional correlates of serotonin 5HT1 recognition sites. J Recept Res 8: 59–81Google Scholar
  26. Johnston A, File SE (1988) Profiles of the antipanic compounds, triazolobenzodiazepines and phenelzine, in two animal tests of anxiety. Psychiatry Res 25: 81–90Google Scholar
  27. Kaesermann HP (1986) Stretched attend posture, a non-social form of ambivalence, is sensitive to a conflict-reducing drug action. Psychopharmacology 89: 31–37Google Scholar
  28. Kaesermann HP, Dixon AK (1986) Further validation of the stretched attend posture test, a simple behavioral conflict test in mice. Psychopharmacology 89: S19Google Scholar
  29. Kahn RS, Wetzler S (1991)m-Chlorophenylpiperazine as a probe of serotonin function. Biol Psychiatry 30: 1139–1166Google Scholar
  30. Kennett GA, Curzon G (1988) Evidence that mCPP may have behavioural effects mediated by central 5-HT1C receptors. Br J Pharmacol 94: 137–147Google Scholar
  31. Kennett GA, Whitton P, Shah K, Curzon G (1989) Anxiogenic-like effects of mCPP and TFMPP in animal models are opposed by 5-HT1C receptor antagonists. Eur J Pharmacol 164: 445–454Google Scholar
  32. Klint T (1991) Effects of 8-OH-DPAT and buspirone in a passive avoidance test and in the elevated plus-maze test in rats. Behav Pharmacol 2: 481–489Google Scholar
  33. Lee C, Rodgers RJ (1990) Antinociceptive effects of elevated plus-maze exposure: influence of opiate receptor manipulations. Psychopharmacology 102: 507–513Google Scholar
  34. Lee C, Rodgers RJ (1991) Effects of benzodiazepine antagonist, flumazenil, on antinociceptive and behavioural responses to the elevated plus-maze in mice. Neuropharmacology 30: 1263–1267Google Scholar
  35. Lister RG (1987) The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology 92: 180–185Google Scholar
  36. Middlemiss DN, Fozard JR (1983) 8-Hydroxy-2-(di-n-propylamino)-tetralin discriminates between subtypes of the 5-HT1 recognition site. Eur J Pharmacol 90: 151–153Google Scholar
  37. Montgomery KC (1955) The relation between fear induced by novel stimulation and exploratory behaviour. J Comp Physiol Psychol 48: 254–260Google Scholar
  38. Moser PC (1989) An evaluation of the elevated plus-maze test using the novel anxiolytic buspirone. Psychopharmacology 99: 48–53Google Scholar
  39. Moser PC, Tricklebank MD, Middlemiss DN, Mir AK, Hibert MF, Fozard JR (1990) Characterisation of MDL 73005EF as a 5-HT1A selective ligand and its effects in animal models of anxiety; comparison with buspirone 8-OH-DPAT and diazepam. Br J Pharmacol 99: 343–349Google Scholar
  40. Pellow S, File SE (1986) Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in the rat. Pharmacol Biochem Behav 24: 525–529Google Scholar
  41. Pellow S, Chopin P, File SE, Briley M (1985) Validation of open closed arm entires in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 14: 149–167Google Scholar
  42. Pellow S, Johnston AL, File SE (1987) Selective agonists and antagonists for 5-hydroxytryptamine receptor subtypes, and interactions with yohimbine and FG 7142 using the elevated plus-maze test in the rat. J Pharm Pharmacol 39: 917–928Google Scholar
  43. Pollard GT, Howard JL (1988) Effects of chlordiazepoxide, pentobarbital, buspirone, chlorpromazine, and morphine in the stretched attend posture (SAP) test. Psychopharmacology 94: 433–444Google Scholar
  44. Rago L, Kiivet, R-A, Harro, J, Pold M (1988) Behavioural differences in an elevated plus-maze: correlation between anxiety and decreased number of GABA and benzodiazepine receptors in mouse cerebral cortex. Naunyn-Schmiedberg's Arch Pharmacol 337: 675–678Google Scholar
  45. Rodgers RJ (1991) A step in the right direction: comment on “5-HT and mechanisms of defence”. J Psychopharmacol 5: 316–319Google Scholar
  46. Rodgers RJ, Cole JC, Cobain MR Daly P, Doran PJ, Eells JR, Wallis P (1992a) Anxiogenic-like effects of fluprazine and eltoprazine in the mouse elevated plus-maze: profile comparisons with 8-OH-DPAT, CGS12066B, TFMPP and mCPP. Behav Pharmacol 3: 621–634Google Scholar
  47. Rodgers RJ, Lee C, Shepherd JK (1992b) Effects of diazepam on behavioural and antinociceptive responses to the elevated plus-maze in male mice depend upon treatment regimen and prior maze experience. Psychopharmacology 106: 102–110Google Scholar
  48. Shepherd JK (1992) Preliminary evaluation of an elevated “zeromaze” as a model of anxiety in laboratory rats. J Psychopharmacol 6 [A56]: 223Google Scholar
  49. Shepherd JK, Flores T, Rodgers RJ, Blanchard RJ (1992) The anxiety/defense test battery: influence of gender and ritanserin treatment on antipredator defensive behavior. Physiol Behav 51: 277–285Google Scholar
  50. Shepherd JK, Grewal SS, Fletcher, Bill D, Dourish CT (1993) Pharmacological evaluation of the elevated “zero-maze” as a model of anxiety in rats. Br J Pharmacol 110: 13PGoogle Scholar
  51. Soderpalm S, Hjorth S, Engel JA (1989) Effects of 5-HT1A receptor agonists and L-5-HTP in Montgomery's conflict test. Pharmacol Biochem Behav 32: 259–265Google Scholar
  52. Suzuki T, Inayama M, Misawa M (1990) The effect of diazepam on exploratory behavior and its strain differences in inbred rats. Jpn J Psychopharmacol 10: 307–314Google Scholar
  53. Tomkins DM, Costall B, Kelly ME (1990) Release of suppressed behaviour of rats on the elevated X-maze by 5-HT3 antagonists injected into the basolateral amygdala. J Psychopharmacol 4: 262Google Scholar
  54. Treit D, (1991) Anxiolytic effects of benzodiazepines and 5-HT1A agonists: animal models. In: Rodgers RJ, Cooper SJ (eds) 5-HT1A agonists, 5-HT3 antagonists and benzodiazepines — their comparative behavioural pharmacology. Wiley, Chichester, pp 107–131Google Scholar
  55. Treit D, Fundytus M (1988) Thigmotaxis as a test for anxiolytic activity in rats. Pharmacol Biochem Behav 31: 958–962Google Scholar
  56. Treit D, Menard J, Royan C (1993) Anxiogenic stimuli in the elevated plus-maze. Pharmacol Biochem Behav 44: 463–469Google Scholar
  57. Upton N, Blackburn TP (1991) Anxiolytic-like activity of the selective 5-HT3 receptor antagonist, BRL 46470A, in the rat elevated X-maze. Br J Pharmacol 102: 253PGoogle Scholar
  58. Vasar E, Peuranen E, Oopok T, Harro J, Mannisto PT (1993) Ondansetron, an antagonist of 5-HT3 receptors, antagonises the anti-exploratory effect of caerulein, an agonist of CCK receptors, in the elevated plus-maze. Psychopharmacology 110: 213–218Google Scholar
  59. Wilkinson LO, Dourish CT (1991) Serotonin and animal behaviour. In: Peroutka SJ (ed) Serotonin receptor subtypes: basic and clinical aspects. Alan R. Liss, New York, pp 149–212Google Scholar
  60. Wright IK, Heaton M, Upton N, Marsden CA (1992) Comparison of acute and chronic treatment of various serotonergic agents with those of diazepam and idazoxan in the rat elevated X-maze. Psychopharmacology 107: 405–414Google Scholar

Copyright information

© Springer-Verlag 1994

Authors and Affiliations

  • Jon K. Shepherd
    • 1
  • Savraj S. Grewal
    • 1
  • Allan Fletcher
    • 1
  • David J. Bill
    • 1
  • Colin T. Dourish
    • 1
  1. 1.Department of NeuropharmacologyWyeth Research (UK) LtdMaidenheadUK

Personalised recommendations